ArticleFrontiers in medicine2026
Risk-based redesign of internal quality control procedures for emergency immunoassays in clinical laboratories: a multicenter study from China.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although clinical laboratories routinely implement internal quality control (IQC) to ensure the reliability of test results, emergency immunoassay testing introduces unique operational challenges. To mitigate financial burdens, some laboratories arbitrarily extend IQC batch lengths or reduce the number of quality control (QC) samples per analytical run. This study evaluated baseline IQC practices for emergency immunoassays across five laboratories in Suining, China, aiming to provide evidence-based guidance for regional quality improvement. Methods: Average daily test volumes, external quality assessment (EQA) results, and historical IQC data were retrospectively collected from the five laboratories. Sigma metrics were calculated for each analyte. Concurrently, the "Westgard Sigma Rule with Run Length" nomogram was applied to design individualized, risk-based statistical quality control (RB-SQC) procedures. Results: All emergency immunoassays, except for serum procalcitonin, were subjected to routine IQC across all five laboratories; notably, certain analytes followed an extended 72-h IQC batch interval. Within individual laboratories, QC rules, the number of QC results per batch, and batch lengths were consistent across analytes but varied between laboratories. Under the current QC scheme, the QC utilization rate (N/M-1) was 0.087 (0.047-0.143), which decreased significantly to 0.020 (0.004-0.133) after implementing RB-SQC procedures (N/M-2; Conclusions: Baseline IQC practices for emergency immunoassays in the surveyed laboratories were inconsistent and lacked a standardized risk-based foundation. We recommend that clinical laboratories implement individualized RB-SQC protocols designed using the Westgard Sigma Rule with Run Length nomogram, and periodically reassess their appropriateness based on updated sigma metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.